← Leaderboards
Max O'Donnell
Boston University Medical Campus
$9,472,250
Attributed
$13,589,289
Total exposure
11
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2009–25$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,589,289 · 11
By mechanism
R01$11,102,285 · 4
R21$1,556,390 · 4
K23$669,195 · 1
K24$209,757 · 1
F32$51,662 · 1
Top collaborators
- Michelle H Larsen5 shared
- Nesri Padayatchi5 shared
- Kathy Rivet Amico2 shared
- William Robert Jacobs2 shared
- Rubeshan Perumal2 shared
- Yael R Hirsch-Moverman1 shared
- Kogieleum Naidoo1 shared
- Threnesan Naidoo1 shared
Most similar at Boston University Medical Campus
Same institution · by research overlap
- Lora L Sabin$2,935,918
Others in their field
Top investigators on “Tuberculosis”
- Judith S. Currier · University Of California Los Angeles$301,722,065
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$297,204,160
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$267,912,117
- Lawrence Corey · Fred Hutchinson Cancer Center$255,939,398
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$200,192,298
- Sharon A Nachman · Johns Hopkins University$194,852,226
Research focus
TuberculosisDrug ResistanceDrug Resistance In TuberculosisResistanceTreatment OutcomePharmaceutical PreparationsSouth AfricaMortalityInnovationTuberculosis TreatmentAntimycobacterial AgentsTuberculosis DrugsTransmission ProcessRegimenComplexIncidenceHiv/TbCaringMycobacterium TuberculosisMultidrug-Resistant TuberculosisMedication ComplianceNovel TherapeuticsAdherencePersons
Grant awards (33)
Advanced Genotypic and Phenotypic monitoring of Drug Resistant TB to Improve TB Treatment Outcomes$846,347
R01 · FY2025 · AI
Rapid phenotypic detection of complex and emergent TB drug-resistance using a next-generation nanoluciferase reporter phage$731,742
R01 · FY2025 · AI · contact PI
Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa$280,026
R01 · FY2025 · AI · contact PI
Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa$256,000
R01 · FY2025 · AI · contact PI
Mobilizing Innovative Strategies to Improve TB Diagnosis and Retention in the TB Care Cascade for Migrant Communities in New York City$253,497
R21 · FY2025 · AI · contact PI
Mentoring Multidisciplinary Research in MDR-TB Adherence and the Emergent Drug Resistance$209,757
K24 · FY2025 · AI · contact PI
Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa$14,040
R01 · FY2025 · AI · contact PI
Rapid phenotypic detection of complex and emergent TB drug-resistance using a next-generation nanoluciferase reporter phage$746,037
R01 · FY2024 · AI · contact PI
Advanced Genotypic and Phenotypic monitoring of Drug Resistant TB to Improve TB Treatment Outcomes$723,278
R01 · FY2024 · AI
Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa$566,451
R01 · FY2024 · AI · contact PI
Nanoluciferase reporter phage for rapid phenotypic characterization of resistance to next-generation antimycobacterial agents$179,286
R21 · FY2024 · AI · contact PI
Rapid phenotypic detection of complex and emergent TB drug-resistance using a next-generation nanoluciferase reporter phage$800,726
R01 · FY2023 · AI · contact PI
Advanced Genotypic and Phenotypic monitoring of Drug Resistant TB to Improve TB Treatment Outcomes$726,583
R01 · FY2023 · AI
Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa$583,702
R01 · FY2023 · AI · contact PI
Nanoluciferase reporter phage for rapid phenotypic characterization of resistance to next-generation antimycobacterial agents$241,715
R21 · FY2023 · AI · contact PI
Advanced Genotypic and Phenotypic monitoring of Drug Resistant TB to Improve TB Treatment Outcomes$729,791
R01 · FY2022 · AI
Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa$625,958
R01 · FY2022 · AI · contact PI
Advanced Genotypic and Phenotypic monitoring of Drug Resistant TB to Improve TB Treatment Outcomes$783,184
R01 · FY2021 · AI
Targeted next-generation sequencing to enhance detection and genomic characterization of Mycobacterium tuberculosis and high-impact bacterial pathogens among HIV-infected adults with sepsis in Uganda$282,467
R21 · FY2021 · AI · contact PI
Promoting Engagement in the Drug Resistant TB/HIV Care Continuum in South Africa$502,311
R01 · FY2020 · AI · contact PI
Targeted next-generation sequencing to enhance detection and genomic characterization of Mycobacterium tuberculosis and high-impact bacterial pathogens among HIV-infected adults with sepsis in Uganda$185,590
R21 · FY2020 · AI · contact PI
Promoting Engagement in the Drug Resistant TB/HIV Care Continuum in South Africa$516,583
R01 · FY2019 · AI · contact PI
Impact of a multimodal intervention to reduce dual stigma and improve treatment outcomes in HIV/Drug-resistant TB co-infected patients in KwaZulu-Natal, South Africa$186,251
R21 · FY2019 · TW · contact PI
Promoting Engagement in the Drug Resistant TB/HIV Care Continuum in South Africa$543,856
R01 · FY2018 · AI · contact PI
Impact of a multimodal intervention to reduce dual stigma and improve treatment outcomes in HIV/Drug-resistant TB co-infected patients in KwaZulu-Natal, South Africa$227,584
R21 · FY2018 · TW · contact PI
Promoting Engagement in the Drug Resistant TB/HIV Care Continuum in South Africa$543,440
R01 · FY2017 · AI · contact PI
Promoting Engagement in the Drug Resistant TB/HIV Care Continuum in South Africa$582,230
R01 · FY2016 · AI · contact PI
Biomarker for XDR-TB Treatment Response and Drug Resistance in HIV Endemic Area$134,163
K23 · FY2016 · AI · contact PI
Biomarker for XDR-TB Treatment Response and Drug Resistance in HIV Endemic Area$134,163
K23 · FY2015 · AI · contact PI
Biomarker for XDR-TB Treatment Response and Drug Resistance in HIV Endemic Area$134,163
K23 · FY2014 · AI · contact PI
Biomarker for XDR-TB Treatment Response and Drug Resistance in HIV Endemic Area$134,163
K23 · FY2013 · AI · contact PI
Biomarker for XDR-TB Treatment Response and Drug Resistance in HIV Endemic Area$132,543
K23 · FY2012 · AI · contact PI
Treatment Outcomes for Patients with Extensively Drug Resistant Tuberculosis$51,662
F32 · FY2009 · AI · contact PI